» Articles » PMID: 33786569

Respiratory Sarcopenia and Sarcopenic Respiratory Disability: Concepts, Diagnosis, and Treatment

Overview
Date 2021 Mar 31
PMID 33786569
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

The condition of muscle fiber atrophy and weakness that occurs in respiratory muscles along with systemic skeletal muscle with age is known as respiratory sarcopenia. The Japanese Working Group of Respiratory Sarcopenia of the Japanese Association of Rehabilitation Nutrition narratively reviews these areas, and proposes the concept and diagnostic criteria. We have defined respiratory sarcopenia as "whole-body sarcopenia and low respiratory muscle mass followed by low respiratory muscle strength and/or low respiratory function." Respiratory sarcopenia can be caused by various factors such as aging, decreased activity, undernutrition, disease, cachexia, and iatrogenic causes. We have also created an algorithm for diagnosing respiratory sarcopenia. Respiratory function decreases with age in healthy older people, along with low respiratory muscle mass and strength. We have created a new term, "Presbypnea," meaning a decline in respiratory function with aging. Minor functional respiratory disability due to aging, such as that indicated by a modified Medical Research Council level 1 (troubled by shortness of breath when hurrying or walking straight up hill), is an indicator of presbypnea. We also define sarcopenic respiratory disability as "a disability with deteriorated respiratory function that results from respiratory sarcopenia." Sarcopenic respiratory disability is diagnosed if respiratory sarcopenia is present with functional disability. Cases of respiratory sarcopenia without functional disability are diagnosed as "at risk of sarcopenic respiratory disability." Functional disability is defined as a modified Medical Research Council grade of 2 or more. Rehabilitation nutrition, treatment that combines rehabilitation and nutritional management, may be adequate to prevent and treat respiratory sarcopenia and sarcopenic respiratory disability.

Citing Articles

Epigenetic factors and inflammaging: FOXO3A as a potential biomarker of sarcopenia and upregulation of DNMT3A and SIRT3 in older adults.

Bogucka D, Wajda A, Stypinska B, Radkowski M, Targowski T, Modzelewska E Front Immunol. 2025; 16:1467308.

PMID: 40034697 PMC: 11872893. DOI: 10.3389/fimmu.2025.1467308.


The systemic inflammation response index as risks factor for all-cause and cardiovascular mortality among individuals with respiratory sarcopenia.

Liu Y, Yin X, Guo Y, Xu J, Shao R, Kong Y BMC Pulm Med. 2025; 25(1):90.

PMID: 40011897 PMC: 11863901. DOI: 10.1186/s12890-025-03525-z.


Association Between Chronic Obstructive Pulmonary Disease and Low Muscle Mass in Korean Adults.

Lee D J Clin Med. 2025; 14(4).

PMID: 40004664 PMC: 11856872. DOI: 10.3390/jcm14041134.


Pathogenesis of influenza and SARS-CoV-2 co-infection at the extremes of age: decipher the ominous tales of immune vulnerability.

Mai K, Pan W, Lin Z, Wang Y, Yang Z Adv Biotechnol (Singap). 2025; 3(1):5.

PMID: 39883362 DOI: 10.1007/s44307-025-00057-9.


Effects of respiratory sarcopenia on the postoperative course in elderly lung cancer patient: a retrospective study.

Han D, Na K, Yun T, Park J, Na B, Park S J Cardiothorac Surg. 2025; 20(1):71.

PMID: 39827359 PMC: 11742806. DOI: 10.1186/s13019-024-03185-w.


References
1.
Grosu H, Ost D, Lee Y, Song J, Li L, Eden E . Diaphragm Muscle Thinning in Subjects Receiving Mechanical Ventilation and Its Effect on Extubation. Respir Care. 2017; 62(7):904-911. PMC: 6373860. DOI: 10.4187/respcare.05370. View

2.
Costes F, Gosker H, Feasson L, Desgeorges M, Kelders M, Castells J . Impaired exercise training-induced muscle fiber hypertrophy and Akt/mTOR pathway activation in hypoxemic patients with COPD. J Appl Physiol (1985). 2015; 118(8):1040-9. DOI: 10.1152/japplphysiol.00557.2014. View

3.
Fernandes L, de Oliveira I, Fernandes P, Neto J, Farias M, de Freitas N . Impact of Heart Transplantation on the Recovery of Peripheral and Respiratory Muscle Mass and Strength in Patients With Chronic Heart Failure. Transplant Direct. 2018; 4(11):e395. PMC: 6233658. DOI: 10.1097/TXD.0000000000000837. View

4.
Martinez-Arnau F, Fonfria-Vivas R, Buigues C, Castillo Y, Molina P, Hoogland A . Effects of Leucine Administration in Sarcopenia: A Randomized and Placebo-controlled Clinical Trial. Nutrients. 2020; 12(4). PMC: 7230494. DOI: 10.3390/nu12040932. View

5.
Nishimura Y, Maeda H, Tanaka K, Hashimoto A, Hashimoto Y, Yokoyama M . [The effect of aging on respiratory muscle function]. Nihon Kyobu Shikkan Gakkai Zasshi. 1991; 29(7):795-801. View